Is Symbiox Investme overvalued or undervalued?

As of 7 November 2025, the valuation grade for Symbiox Investme has moved from fair to expensive, indicating that the company is currently overvalued. The key ratios reflect this assessment, with a PE ratio of 36.70, an EV to EBIT of -4.23, and a PEG ratio of 0.23. These figures suggest that the company's valuation metrics are significantly higher than what would typically be expected in the market.
In comparison to its peers, Symbiox Investme's PE ratio is higher than Bajaj Finserv's 35.3 and lower than Bajaj Finance's 38.09, but it is notably less favorable than Life Insurance's attractive PE of 11.44. The negative EV to EBIT and EV to EBITDA ratios further reinforce the notion of overvaluation. Recent stock performance shows that while Symbiox has outperformed the Sensex over the past week and month, it has significantly underperformed on a year-to-date and three-year basis, which supports the conclusion that the stock is currently overvalued.